Skip to content
Clinical Trials – home
SlovakiaBack to Slovakia

Clinical trials in Banka

2 clinical trials in Banka, Slovakia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Banka at a glance
2
clinical trials
  • Recruiting now0
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 trials in Banka

Open in trial search

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Breast cancer+1

Not recruiting

Study of PF-07220060 and Letrozole for Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Pfizer Inc.

Other cities in Slovakia

The busiest research cities in the country

All 92 cities in Slovakia

Clinical research in Banka

What the registry says about research in the country

01 Neoplasms

In Banka, clinical research is focused on neoplasms, with all active studies centered on breast cancer. The main goal is to better understand how new treatment combinations may improve outcomes for people with hormone-sensitive disease.

  • Advanced/metastatic breast cancer
  • Hormone receptor-positive, HER2-negative breast cancer
  • Testing a new therapy strategy against current treatment options
  • Assessing treatment effectiveness and early tumor response

These studies are exploring whether combining PF-07220060 with standard endocrine treatments can offer better disease control for patients in Slovakia.

02 Breast Cancer Treatment Research

The trials in this city are examining treatment approaches for hormone receptor-positive, HER2-negative breast cancer across both earlier and more advanced disease settings. Research is aimed at refining therapy choices and improving how long cancer stays controlled.

  • Hormone receptor-positive advanced/metastatic breast cancer
  • Neoadjuvant breast cancer treatment
  • Comparing combination therapy with established care
  • Looking at biomarkers such as Ki-67 to understand response

By focusing on both tumor activity and progression control, these studies may help shape more personalized care for patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.